ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2050

Arthralgia Occurring Under Aromatase Inhibitor Treatment For Breast Cancer.  A Prospective Study

Daniel Wendling1, Helene Letho-Gyselinck1, Xavier Guillot2, Clément Prati3 and Xavier Pivot4, 1Service de Rhumatologie, Minjoz University Hospital, Besancon, France, 2Department of Rheumatology, CHRU Besançon, Besançon, France, 3Service de Rhumatologie, CHU J Minjoz, Besancon, France, 4Oncology, CHRU Besançon, Besançon, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Clinical research

  • Tweet
  • Email
  • Print
Session Information

Session Title: Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Treatment with third generation aromatase inhibitors (AI) is associated with occurrence of arthralgia, with an incidence ranging from 25 to 45 %. In these patients, arthralgia may also be related to other conditions such as osteoarthritis,  common tendinitis or auto immune diseases.

The aim of this study was to study patients treated with AI and reporting arthralgia, and comparing patients with new onset to patients with pre existing arthralgia and exacerbation under AI, to look for associated etiologic factors.

Methods:

Patients followed in a tertiary oncology center for breast cancer treated with AI and reporting arthralgia were prospectively screened for rheumatologic clinical evaluation , as well as biologic (ESR, CRP, RF, ANA, ACPA) or imaging (X-Rays of symptomatic regions) investigation. Type of cancer, duration, treatment, type of AI, duration of AI treatment. Patients were divided in two groups : patients with new onset of arthralgia under AI, and patients with pre existing and exacerbation of arthralgia under AI. The two groups are compared using t test for quantitative variables (significance : p less than 0.05).

Results:

Seventy five women were included, mean age (SD):  64.8 (9.2) years, time from cancer diagnosis : 34 (25) months. Adjuvant chemotherapy and/or radiotherapy were noted in respectively 52 and 64 cases. AI was Anastrozole (n = 6), Letrozole (55), Exemestane (14). Mean duration AI treatment  since onset or exacerbation of arthralgia : 179 (224) days. Mean number of painful joints : 7.6 (9.7); locations (number of patients) :shoulder 36, elbow 22, wrist 25, MCP 27, PIP 26, knee 26, MTP28. Mean ESR : 29 (25)mm/h; CRP : 3 (7.6) mg/l). New onset arthralgia : n = 38; pre existing and exacerbation of arthralgia : n = 37. No statistical differences were found between these two groups for type of cancer, presence of chemotherapy or radiotherapy, presence of metastases, duration and type of AI treatment, VAS pain, number and distribution of tender joints, ESR, CRP, ANA, RF, ACPA positivity, and radiographic findings.  Positive lymph nodes and radiographic signs of rotator cuff dysfunction were statistically more frequent in the pre existing and exacerbation group. Some specific diagnoses were done after evaluation : 2 CREST syndrome (one in each group), 1 RA and 1 Sjögren syndrome in the new onset symptom group.

Conclusion: Arthralgia under AI treatment is frequent. Our study argues for an absence of specificity of these arthralgia, without particular difference between new onset or exacerbation of pre existing arthralgia, auto immune disease seem more frequent in the new onset symptom group, and thus possibly related to anti aromatase therapy


Disclosure:

D. Wendling,
None;

H. Letho-Gyselinck,
None;

X. Guillot,
None;

C. Prati,
None;

X. Pivot,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/arthralgia-occurring-under-aromatase-inhibitor-treatment-for-breast-cancer-a-prospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences